In Their Own Words – Patient Descriptions of the Earliest Recognition of HAE Attack Onset

Manning ME, Burnette AF, van Kooten S, Heckmann M, Danese S, Goga L, Guilarte M

HAEA National Summit 2023

Recognizing the Importance of Early On-Demand Treatment in the HAE Attack Journey

Jones DH, Ogbogu P, van Kooten S, Heckmann M, Danese S, Goga L, Magerl M

HAEA National Summit 2023

Preferences of People with Hereditary Angioedema for On-Demand Treatment: A US-Based Qualitative Study

Bukstein DA, Vibha Desai V, Goga L, Czado S, Brown M, Myers K, Audhya PK, Settipane RA, Busse PJ

HAEA National Summit 2023

PB0536: Oral Factor XIIa inhibitor KV998086 protects against FeCl3 induced thrombosis in mice.

Clermont A, Pinckney F, Hill M, Hampton SL, Feener EP

Understanding the complex decision-making associated with on-demand treatment of hereditary angioedema (HAE) attacks

Grumach A, van Kooten S, Heckmann M, Danese S, Goga L, Garcez T

Remaining burden of hereditary angioedema (HAE) attacks despite modern long-term prophylaxis

Betschel S, van Kooten S, Heckmann M, Danese S, Caballero T

Short-Term Prophylaxis with Sebetralstat, an Investigational Oral On-Demand Treatment for Hereditary Angioedema, in KONFIDENT-S

Bernstein JA, Riedl MA, Lumry WR, Audhya PK, Smith MD, Yea CM

Results From a Randomized, Double-Blind, Placebo-Controlled, Phase 1 Trial Evaluating Sebetralstat Pharmacokinetics, Pharmacodynamics, and Safety/Tolerability in Healthy Japanese, Chinese, and White Adults

Hide M, Iverson M, Jhee S, Hansen E, Duckworth EJ, Hampton SL, Yoon E, Honda D

Patients delay treating hereditary angioedema (HAE) attacks with currently available, injectable, on-demand therapies: associated with on-demand treatment of hereditary angioedema (HAE) attacks

Valerieva A, van Kooten S, Heckmann M, Danese S, Goga L, Longhurst H

Sebetralstat Effectiveness in the Treatment of Hereditary Angioedema Attacks Rated Mild or Moderate at Baseline in the Phase 2 Trial

Longhurst HJ, Smith MD, Yea CM, Audhya PK